NO20065694L - Indolderivat med piperidinring - Google Patents
Indolderivat med piperidinringInfo
- Publication number
- NO20065694L NO20065694L NO20065694A NO20065694A NO20065694L NO 20065694 L NO20065694 L NO 20065694L NO 20065694 A NO20065694 A NO 20065694A NO 20065694 A NO20065694 A NO 20065694A NO 20065694 L NO20065694 L NO 20065694L
- Authority
- NO
- Norway
- Prior art keywords
- hydrogen atom
- piperidine ring
- receptor
- indole derivative
- group
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title 1
- 125000003386 piperidinyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004142437 | 2004-05-12 | ||
| PCT/JP2005/008632 WO2005108389A1 (ja) | 2004-05-12 | 2005-05-11 | ピペリジン環を有するインドール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20065694L true NO20065694L (no) | 2007-01-29 |
Family
ID=35310200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20065694A NO20065694L (no) | 2004-05-12 | 2006-12-12 | Indolderivat med piperidinring |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7538123B2 (pt) |
| EP (1) | EP1757599A4 (pt) |
| JP (1) | JP3902221B2 (pt) |
| KR (1) | KR100788862B1 (pt) |
| CN (1) | CN1984900B (pt) |
| AU (1) | AU2005240928B2 (pt) |
| BR (1) | BRPI0510971A (pt) |
| CA (1) | CA2564062C (pt) |
| IL (1) | IL178940A (pt) |
| MX (1) | MXPA06013034A (pt) |
| MY (1) | MY138420A (pt) |
| NO (1) | NO20065694L (pt) |
| NZ (1) | NZ551024A (pt) |
| RU (1) | RU2332413C1 (pt) |
| SA (1) | SA05260119B1 (pt) |
| TW (1) | TWI391387B (pt) |
| WO (1) | WO2005108389A1 (pt) |
| ZA (1) | ZA200609225B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI391387B (zh) * | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
| WO2006082872A1 (ja) * | 2005-02-04 | 2006-08-10 | Eisai R & D Management Co., Ltd. | １－（ピペリジン－４－イル）－１ｈ－インドール誘導体 |
| EP1880995B1 (en) * | 2005-05-11 | 2011-12-21 | Eisai R&D Management Co., Ltd. | Method for producing indole derivative having piperidine ring |
| CN101175751B (zh) * | 2005-05-11 | 2011-03-23 | 卫材R&D管理有限公司 | 具有哌啶环的吲哚衍生物的晶体和其制备方法 |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| JP5147401B2 (ja) * | 2005-09-06 | 2013-02-20 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体 |
| WO2007042325A1 (de) * | 2005-10-13 | 2007-04-19 | Morphochem Aktiengesellschaft für kombinatorische Chemie | 5-chinolinderivate mit antibakterieller aktivität |
| JP2008169191A (ja) * | 2006-02-20 | 2008-07-24 | Eisai R & D Management Co Ltd | 運動ニューロン疾患治療剤 |
| US7541371B2 (en) * | 2006-02-20 | 2009-06-02 | Eisai R&D Management Co., Ltd. | Method for treating a motor neuron disease |
| US20100041905A1 (en) * | 2006-07-18 | 2010-02-18 | Astrazeneca Ab | Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl |
| TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
| TW200831140A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution |
| WO2008101139A1 (en) * | 2007-02-16 | 2008-08-21 | Wyeth | Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution |
| TWI410420B (zh) | 2008-02-05 | 2013-10-01 | Dainippon Sumitomo Pharma Co | 苄基哌啶化合物 |
| US8604189B2 (en) * | 2008-05-30 | 2013-12-10 | Emcure Pharmaceuticals Limited | Process for the preparation of Efavirenz |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| FR2941946B1 (fr) * | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique |
| US8778970B2 (en) | 2009-08-04 | 2014-07-15 | Dainippon Sumitomo Pharma Co., Ltd | Benzyl piperidine compound |
| CA2824970C (en) | 2011-02-11 | 2016-05-03 | Batmark Limited | Inhaler component |
| TW201326180A (zh) | 2011-11-30 | 2013-07-01 | Actelion Pharmaceuticals Ltd | ３，７－二取代八氫－２Ｈ－吡啶并［４，３－ｅ］［１，３］□嗪－２－酮抗生素 |
| US9951038B2 (en) | 2012-12-27 | 2018-04-24 | Purdue Pharma L.P. | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof |
| US9963458B2 (en) | 2012-12-27 | 2018-05-08 | Purdue Pharma L.P. | Indole and indoline-type piperidine compounds and uses thereof |
| AU2014209200B2 (en) * | 2013-01-24 | 2018-11-01 | Minerva Neurosciences, Inc. | Use of phenoxypropylamine compounds to treat depression |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN113717091B (zh) * | 2021-09-28 | 2023-03-10 | 南京医科大学 | 一类吲哚衍生物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545644A (en) * | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| TWI242011B (en) * | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| IT1293807B1 (it) * | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico |
| US20020193383A1 (en) * | 1997-08-01 | 2002-12-19 | Recordati S.A., Chemical And Pharmaceutical Comoany | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring |
| GB9825413D0 (en) * | 1998-11-19 | 1999-01-13 | Lilly Co Eli | Pharmaceutical compounds |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| DE10000739A1 (de) * | 2000-01-11 | 2001-07-12 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| GB2362381A (en) * | 2000-05-18 | 2001-11-21 | Lilly Co Eli | Pharmaceutically active indolyl-piperidines |
| US6844338B2 (en) * | 2000-05-18 | 2005-01-18 | Eli Lilly And Company | Piperidyindoles as serotonin receptor ligands |
| MXPA02012927A (es) * | 2000-07-21 | 2003-05-15 | Lundbeck & Co As H | Derivados de indol utiles para el tratamiento de padecimientos del sistema nervioso central. |
| JP2002114684A (ja) * | 2000-10-03 | 2002-04-16 | Eisai Co Ltd | 尿路疾患治療剤 |
| AU2002364590A1 (en) * | 2001-12-21 | 2003-07-30 | Eisai Co., Ltd. | Hydroxylated indole derivatives and uses thereof |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| GB0306604D0 (en) * | 2003-03-21 | 2003-04-30 | Curidium Ltd | Second medical use |
| TWI391387B (zh) | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
| WO2006082872A1 (ja) | 2005-02-04 | 2006-08-10 | Eisai R & D Management Co., Ltd. | １－（ピペリジン－４－イル）－１ｈ－インドール誘導体 |
| EP1880994A4 (en) | 2005-05-11 | 2010-04-14 | Eisai R&D Man Co Ltd | INDOLE DERIVED CRYSTAL COMPRISING A PIPERIDINE CYCLE AND PROCESS FOR SYNTHESIZING SAID CRYSTAL |
| CN101171249B (zh) | 2005-05-11 | 2010-11-10 | 卫材R&D管理有限公司 | 制备具有哌啶环的吲哚衍生物的方法 |
| US7541371B2 (en) * | 2006-02-20 | 2009-06-02 | Eisai R&D Management Co., Ltd. | Method for treating a motor neuron disease |
-
2005
- 2005-04-28 TW TW094113672A patent/TWI391387B/zh not_active IP Right Cessation
- 2005-05-04 SA SA05260119A patent/SA05260119B1/ar unknown
- 2005-05-06 MY MYPI20052035A patent/MY138420A/en unknown
- 2005-05-11 CA CA2564062A patent/CA2564062C/en not_active Expired - Fee Related
- 2005-05-11 JP JP2006513044A patent/JP3902221B2/ja not_active Expired - Fee Related
- 2005-05-11 AU AU2005240928A patent/AU2005240928B2/en not_active Ceased
- 2005-05-11 RU RU2006143769/04A patent/RU2332413C1/ru not_active IP Right Cessation
- 2005-05-11 EP EP05739307A patent/EP1757599A4/en not_active Withdrawn
- 2005-05-11 MX MXPA06013034A patent/MXPA06013034A/es active IP Right Grant
- 2005-05-11 CN CN2005800234130A patent/CN1984900B/zh not_active Expired - Fee Related
- 2005-05-11 ZA ZA200609225A patent/ZA200609225B/xx unknown
- 2005-05-11 NZ NZ551024A patent/NZ551024A/en not_active IP Right Cessation
- 2005-05-11 WO PCT/JP2005/008632 patent/WO2005108389A1/ja not_active Ceased
- 2005-05-11 KR KR1020067025141A patent/KR100788862B1/ko not_active Expired - Fee Related
- 2005-05-11 BR BRPI0510971-0A patent/BRPI0510971A/pt not_active IP Right Cessation
- 2005-05-11 US US11/579,903 patent/US7538123B2/en not_active Expired - Fee Related
- 2005-05-11 US US11/126,209 patent/US20050256103A1/en not_active Abandoned
-
2006
- 2006-10-30 IL IL178940A patent/IL178940A/en not_active IP Right Cessation
- 2006-12-12 NO NO20065694A patent/NO20065694L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL178940A (en) | 2011-02-28 |
| WO2005108389A1 (ja) | 2005-11-17 |
| AU2005240928B2 (en) | 2010-08-19 |
| IL178940A0 (en) | 2007-03-08 |
| RU2332413C1 (ru) | 2008-08-27 |
| CA2564062C (en) | 2012-07-10 |
| US7538123B2 (en) | 2009-05-26 |
| MY138420A (en) | 2009-06-30 |
| CN1984900A (zh) | 2007-06-20 |
| ZA200609225B (en) | 2008-07-30 |
| TWI391387B (zh) | 2013-04-01 |
| CA2564062A1 (en) | 2005-11-17 |
| MXPA06013034A (es) | 2006-12-20 |
| US20050256103A1 (en) | 2005-11-17 |
| KR100788862B1 (ko) | 2007-12-27 |
| JPWO2005108389A1 (ja) | 2008-03-21 |
| HK1100410A1 (en) | 2007-09-21 |
| TW200540174A (en) | 2005-12-16 |
| KR20070011553A (ko) | 2007-01-24 |
| SA05260119B1 (ar) | 2008-11-17 |
| AU2005240928A1 (en) | 2005-11-17 |
| US20070219179A1 (en) | 2007-09-20 |
| EP1757599A1 (en) | 2007-02-28 |
| EP1757599A4 (en) | 2010-07-14 |
| CN1984900B (zh) | 2010-11-10 |
| NZ551024A (en) | 2009-06-26 |
| RU2006143769A (ru) | 2008-06-20 |
| JP3902221B2 (ja) | 2007-04-04 |
| BRPI0510971A (pt) | 2007-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY138420A (en) | Indole derivative having piperidine ring | |
| AU2022203948B2 (en) | Apoptosis-Inducing Agents | |
| RU2386623C2 (ru) | Новые модуляторы дофаминовой нейротрансмиссии | |
| Feng et al. | Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives | |
| AU2016215033B2 (en) | (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | |
| NO20054952L (no) | 2,3,6-trisubstituerte 4-pyrimidonderivater | |
| NO20072409L (no) | Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser | |
| NO20072115L (no) | Farmasoytiske forbindelser | |
| JP3176935B2 (ja) | ドーパミンリセプタサプタイプ特異性リガンドとしてのｎ―アミノアルキルジベンゾフランカルボキサミド | |
| AR071050A1 (es) | Compuestos derivados de alcoxi , composiciones farmaceuticas de ellos , compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos | |
| HUP0203874A2 (hu) | Helyettesített 4-(fenil-N-alkil)piperazin és piperidinszármazékok és alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények | |
| NO20075312L (no) | N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling | |
| NO170081B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolderivater med aktivitet paa kolinerge system | |
| WO2007143523A8 (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| PE20070491A1 (es) | Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina | |
| TNSN08499A1 (en) | CRYSTALLINE FORMS OF 11 ß-(4-ACETYLPHENYL)-20,20,21,21,21-PENTAFLUOR-17- HYDROXY-19-NOR-17α-PREGNA-4,9-DIEN-3-ONE | |
| EP3174860A1 (en) | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| WO2009095792A3 (en) | Substituted heteroarylamide diazepinopyrimidone derivatives | |
| NO20073271L (no) | Nye pyridotienopyrimidinderivater | |
| Zhang et al. | Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs | |
| ES2374629T3 (es) | Nuevos derivados de bencil(iden)-lactama. | |
| NO20051901L (no) | Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger | |
| NO20080262L (no) | Fremgangsmate for produksjonen av intermediater for fremstilling av tricykliske benzimidazoler | |
| NO20071209L (no) | Pyrrolderivater, deres fremstilling og deres terapeutiske anvendelse | |
| BRPI0415109A (pt) | compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |